国产bbaaaaa片,成年美女黄网站色视频免费,成年黄大片,а天堂中文最新一区二区三区,成人精品视频一区二区三区尤物

首頁(yè)> 美國(guó)衛(wèi)生研究院文獻(xiàn)>Journal of Lipid Research >Thematic Review Series: ApoE and Lipid Homeostasis in Alzheimer’s Disease: Role of LRP1 in the pathogenesis of Alzheimer’s disease: evidence from clinical and preclinical studies
【2h】

Thematic Review Series: ApoE and Lipid Homeostasis in Alzheimer’s Disease: Role of LRP1 in the pathogenesis of Alzheimer’s disease: evidence from clinical and preclinical studies

機(jī)譯：專(zhuān)題回顧系列：阿爾茨海默氏病中的ApoE和脂質(zhì)穩(wěn)態(tài)：LRP1在阿爾茨海默氏病發(fā)病機(jī)理中的作用：來(lái)自臨床和臨床前研究的證據(jù)

代理獲取
本網(wǎng)站僅為用戶(hù)提供外文OA文獻(xiàn)查詢(xún)和代理獲取服務(wù)，本網(wǎng)站沒(méi)有原文。下單后我們將采用程序或人工為您竭誠(chéng)獲取高質(zhì)量的原文，但由于OA文獻(xiàn)來(lái)源多樣且變更頻繁，仍可能出現(xiàn)獲取不到、文獻(xiàn)不完整或與標(biāo)題不符等情況，如果獲取不到我們將提供退款服務(wù)。請(qǐng)知悉。
  • 摘要
  • 著錄項(xiàng)
  • 相似文獻(xiàn)
  • 相關(guān)主題

摘要

Among the LDL receptor (LDLR) family members, the roles of LDLR-related protein (LRP)1 in the pathogenesis of Alzheimer’s disease (AD), especially late-onset AD, have been the most studied by genetic, neuropathological, and biomarker analyses (clinical studies) or cellular and animal model systems (preclinical studies) over the last 25 years. Although there are some conflicting reports, accumulating evidence from preclinical studies indicates that LRP1 not only regulates the metabolism of amyloid-β peptides (Aβs) in the brain and periphery, but also maintains brain homeostasis, impairment of which likely contributes to AD development in Aβ-independent manners. Several preclinical studies have also demonstrated an involvement of LRP1 in regulating the pathogenic role of apoE, whose gene is the strongest genetic risk factor for AD. Nonetheless, evidence from clinical studies is not sufficient to conclude how LRP1 contributes to AD development. Thus, despite very promising results from preclinical studies, the role of LRP1 in AD pathogenesis remains to be further clarified. In this review, we discuss the potential mechanisms underlying how LRP1 affects AD pathogenesis through Aβ-dependent and -independent pathways by reviewing both clinical and preclinical studies. We also discuss potential therapeutic strategies for AD by targeting LRP1.
機(jī)譯：在LDL受體（LDLR）家族成員中，通過(guò)遺傳，神經(jīng)病理學(xué)和生物標(biāo)志物分析，對(duì)LDLR相關(guān)蛋白（LRP）1在阿爾茨海默氏?。ˋD），尤其是遲發(fā)性AD發(fā)病機(jī)理中的作用進(jìn)行了研究最多（臨床研究）或細(xì)胞和動(dòng)物模型系統(tǒng)（臨床前研究）在過(guò)去的25年中。盡管有一些相互矛盾的報(bào)道，但臨床前研究的積累證據(jù)表明，LRP1不僅調(diào)節(jié)大腦和周?chē)牡矸蹣应码模ˋβ）的代謝，而且還維持腦穩(wěn)態(tài)，其損害可能促進(jìn)Aβ中AD的發(fā)展-獨(dú)立的方式。幾項(xiàng)臨床前研究還表明，LRP1參與調(diào)節(jié)apoE的致病作用，而apoE的基因是AD的最強(qiáng)遺傳危險(xiǎn)因素。但是，臨床研究的證據(jù)不足以得出LRP1如何促進(jìn)AD發(fā)育的結(jié)論。因此，盡管臨床前研究取得了令人鼓舞的結(jié)果，但LRP1在A(yíng)D發(fā)病機(jī)制中的作用仍有待進(jìn)一步闡明。在本文中，我們通過(guò)回顧臨床和臨床前研究，探討了LRP1如何通過(guò)Aβ依賴(lài)性和非依賴(lài)性途徑影響AD發(fā)病機(jī)制的潛在機(jī)制。我們還討論了針對(duì)LRP1的AD潛在治療策略。

著錄項(xiàng)

相似文獻(xiàn)

  • 外文文獻(xiàn)
  • 中文文獻(xiàn)
  • 專(zhuān)利
代理獲取

客服郵箱：kefu@zhangqiaokeyan.com

京公網(wǎng)安備：11010802029741號(hào) ICP備案號(hào)：京ICP備15016152號(hào)-6 六維聯(lián)合信息科技 (北京) 有限公司?版權(quán)所有

  • 客服微信

  • 服務(wù)號(hào)